Dr. James L. Gulley on Atezolizumab, Pembrolizumab, and Avelumab's Potential Uses in Bladder Cancer
Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer, despite some widely-used agents, such as nivolumab and pembrolizumab, already being approved for other cancer types like melanoma and lung cancer, though not bladder cancer.
James L. Gulley, MD, PhD, chief of the Genitouriniy Malignancies Branch, director of Medical Oncology Service, National Cancer Institute, discusses the potential shift of the treatment paradigm in bladder cancer. Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer.
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
October 28th 2024TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.
Read More
